Treatment of chronic viral hepatitis С with "sofosbuvir-ledipasvir" combination in patients with dialysis-dependent chronic kidney disease
https://doi.org/10.28996/2618-9801-2018-4-411-415
Abstract
Background: the results of studies on the efficiency and safety of direct-acting antivirals became available only in recent years. Data from two randomized clinical trials (RUBY-1 and C-SURFER) allowed the use of a combination of Grazoprevir-Elbasvir and Ombitasvir-Paritaprevir-Ritonavir in patients with hepatitis C and CKD on hemodialysis. However, because of the high cost and absence of government’s medical insurance, they are not available to most patients. Therefore, generic drugs became an alternative in Kyrgyzstan. One of them is a combination of Sofosbuvir and Ledipasvir. The accumulated data from different single-centered studies suggests safety and effectiveness of its use in the treatment of patients with hepatitis C and End Stage Renal Disease. Aim of this article is to show the result of the safe and effective use of an antiviral drug of direct action in a patient on hemodialysis with systemic vasculitis on the background of maintenance therapy with glucocorticosteroids. Methods: we report on the 55-year female patient on maintenance hemodialysis with Systemic vasculitis and Hepatitis C, who received combination of direct acting anti-viral drugs such as Sofosbuvir and Ledipasvir. Results: HCV RNA was negative after 2 weeks of treatment. Therapy was well tolerated without adverse effects. There was no necessity to correct HD or main disease’s treatment. Sustained virological response was achieved after 24 weeks. Conclusion: full dosage of Sofosbuvir-Ledipasvir therapy for hepatitis C patient on HD with systemic vasculitis was effective and safe without discontinuation or severe side effects. However, final conclusion about safety and efficacy of such treatment must be based on prospective multicenter studies.
About the Authors
A. . Asanbek K.
Osh State University; Hemodialysis Center YURFA
Russian Federation
Russian Federation
G. T. Karataeva
Osh State University; Osh Interregional United Clinical Hospital
Russian Federation
Russian Federation
References
1. Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int. 2013 Oct;17(4):532-41.
2. Holden RM, Harman GJ, Wang M, et al. Major Bleeding in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN. 2008;3(1):105-110.
3. Saeed F, Agrawal N, Greenberg E, Holley JL. Lower Gastrointestinal Bleeding in Chronic Hemodialysis Patients. International Journal of Nephrology. 2011;2011:272535.
4. Kidney Disease: Improving Global Outcomes (KDIGO) KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;(109):S1-99.
5. Meyrier A, Lindley EJ, Boyle G, et al. How plausible is transmission of hepatitis C virus via the haemodialysis circuit? NDT Plus. 2011;4(6):434-436.
6. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-357.
7. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000 Oct;11(10):1896-902.
8. Goodkin DA, Bieber B, Jadoul M, et al. Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN. 2017;12(2):287-297.
9. Fabrizi F, Dixit V, Messa P, et al. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J Viral Hepat. 2014 Oct;21(10):681-9.
10. Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet 2015;54:677-690.
11. Sovaldi. 2015. Sofosbuvir. Summary of Product Characteristics, Gilead Sciences, Hayes, UK. Food & Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204671s004lbl.pdf. Last accessed: January 2016.
12. Akhil MS, Kirushnan B, Martin M, et al. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology (Carlton). 2018 May;23(5):446-452.
13. He YL, Yang SJ, Hu CH, et al. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis. Aliment Pharmacol Ther. 2018 Feb;47(4):526-532.
14. Colombo M, Aghemo A, Liu H, et al. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial. Ann Intern Med. 2017 Jan 17;166(2):109-117.
15. Aggarwal A, Yoo ER, Perumpail RB, et al. Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. J Clin Transl Hepatol. 2017 Mar 28;5(1):23-26.
16. Choudhary NS, Kumar A, Bodh V, et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol. 2017 Mar;36(2):113-116.
17. Desnoyer, A., Pospai, D., Lê, M.P., et al., Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis, Journal of Hepatology (2016) Jul;65(1):40-47.
18. Khan MQ, Moreno AD, Joseph N, et al. Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis. ACG Case Rep J. 2017 Feb 1;4:e21.
Review
For citations:
Asanbek K. A., Karataeva G.T. Treatment of chronic viral hepatitis С with "sofosbuvir-ledipasvir" combination in patients with dialysis-dependent chronic kidney disease. Nephrology and Dialysis. 2018;20(4):411-415. (In Russ.) https://doi.org/10.28996/2618-9801-2018-4-411-415
Views:
56
Email this article 